Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Asset Writedowns and Impairment (2016 - 2026)

Myriad Genetics has reported Asset Writedowns and Impairment over the past 16 years, most recently at $2.7 million for Q4 2025.

  • Quarterly Asset Writedowns and Impairment fell 93.72% to $2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $46.5 million through Dec 2025, down 17.84% year-over-year, with the annual reading at $319.4 million for FY2025, 464.31% up from the prior year.
  • Asset Writedowns and Impairment was $2.7 million for Q4 2025 at Myriad Genetics, down from $43.0 million in the prior quarter.
  • Over five years, Asset Writedowns and Impairment peaked at $43.0 million in Q4 2024 and troughed at $800000.0 in Q3 2024.
  • The 4-year median for Asset Writedowns and Impairment is $6.4 million (2021), against an average of $10.4 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 93.72% in 2025 against a maximum downside of 93.72% in 2025.
  • A 4-year view of Asset Writedowns and Impairment shows it stood at $6.6 million in 2021, then dropped by 6.06% to $6.2 million in 2022, then skyrocketed by 593.55% to $43.0 million in 2024, then crashed by 93.72% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Asset Writedowns and Impairment are $2.7 million (Q4 2025), $43.0 million (Q4 2024), and $800000.0 (Q3 2024).